Payment overview · 2025
General Payments
$360.88
20 reported records · 14 companies
Healthcare provider profile · identity verified
Thomas Gregory Chaisson, MD
Allopathic & Osteopathic Physicians|General Practice · THIBODAUX, LA · NPI 1902895279
Verified facts
What the public records show
CMS Open Payments records show Thomas Gregory Chaisson, MD received $360.88 in general payments during 2025 across 20 reported records.
Novo Nordisk Inc accounted for 17.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $64.50 | 17.9% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $49.13 | 13.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $45.82 | 12.7% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $28.33 | 7.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.52 | 6.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.63 | 6.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.60 | 5.4% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $18.10 | 5.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.46 | 4.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.21 | 4.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.00 | 4.2% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $14.53 | 4.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.54 | 3.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.51 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $360.88 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $49.13 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $45.82 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.05 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $28.45 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $28.33 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.52 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.63 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $18.10 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $14.68 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $14.53 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.54 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 145 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 67 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 91 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
64 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
91 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
145 | 16 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1040 | 228 |
| Alprazolam | Alprazolam | 446 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 421 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 349 | 68 |
| Gabapentin | Gabapentin | 340 | 64 |
| Montelukast Sodium | Montelukast Sodium | 270 | 55 |
| Citalopram Hbr | Citalopram Hydrobromide | 268 | 62 |
| Atorvastatin Calcium | Atorvastatin Calcium | 266 | 64 |
| Metformin Hcl | Metformin Hcl | 266 | 70 |
| Glimepiride | Glimepiride | 244 | 53 |
| Lisinopril | Lisinopril | 226 | 56 |
| Losartan Potassium | Losartan Potassium | 221 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 221 | 43 |
| Omeprazole | Omeprazole | 210 | 46 |
| Paroxetine Hcl | Paroxetine Hcl | 205 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 204 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 201 | 51 |
| Escitalopram Oxalate | Escitalopram Oxalate | 196 | 43 |
| Sertraline Hcl | Sertraline Hcl | 182 | 39 |
| Clonazepam | Clonazepam | 170 | 27 |
| Memantine Hcl | Memantine Hcl | 158 | 27 |
| Allopurinol | Allopurinol | 154 | 40 |
| Eliquis | Apixaban | 145 | 16 |
| Simvastatin | Simvastatin | 144 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 140 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 128 | 32 |
| Famotidine | Famotidine | 127 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 124 | 22 |
| Meloxicam | Meloxicam | 123 | 49 |
| Azithromycin | Azithromycin | 122 | 109 |
| Donepezil Hcl | Donepezil Hcl | 122 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 118 | 29 |
| Carvedilol | Carvedilol | 116 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 116 | 20 |
| Mirtazapine | Mirtazapine | 105 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 19 |
| Metformin Hcl Er | Metformin Hcl | 103 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 102 | 33 |
| Meclizine Hcl | Meclizine Hcl | 100 | 29 |
| Trazodone Hcl | Trazodone Hcl | 95 | 23 |
| Doxazosin Mesylate | Doxazosin Mesylate | 94 | 17 |
| Potassium Chloride | Potassium Chloride | 92 | 21 |
| Ozempic | Semaglutide | 91 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 90 | 17 |
| Colestipol Hcl | Colestipol Hcl | 89 | 21 |
| Atenolol | Atenolol | 88 | 18 |
| Furosemide | Furosemide | 88 | 21 |
| Lorazepam | Lorazepam | 87 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 86 | 74 |
| Zolpidem Tartrate | Zolpidem Tartrate | 86 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 84 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 75 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 73 | 19 |
| Bupropion Xl | Bupropion Hcl | 72 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 23 |
| Jardiance | Empagliflozin | 67 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 67 | 18 |
| Mounjaro | Tirzepatide | 65 | 12 |
| Synthroid | Levothyroxine Sodium | 64 | 16 |
| Celecoxib | Celecoxib | 63 | 14 |
| Eszopiclone | Eszopiclone | 63 | 18 |
| Temazepam | Temazepam | 63 | suppressed |
| Prednisone | Prednisone | 61 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 20 |
| Levofloxacin | Levofloxacin | 55 | 51 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 54 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 53 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 28 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 51 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 11 |
| Cephalexin | Cephalexin | 48 | 34 |
| Diazepam | Diazepam | 48 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 47 | 28 |
| Divalproex Sodium | Divalproex Sodium | 46 | suppressed |
| Torsemide | Torsemide | 46 | suppressed |
| Amoxicillin | Amoxicillin | 45 | 43 |
| Januvia | Sitagliptin Phosphate | 45 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 45 | suppressed |
| Estradiol | Estradiol | 43 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 28 |
| Irbesartan | Irbesartan | 40 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 27 |
| Fluconazole | Fluconazole | 39 | 19 |
| Methylprednisolone | Methylprednisolone | 39 | 37 |
| Sucralfate | Sucralfate | 39 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 38 | suppressed |
| Lactulose | Lactulose | 37 | 14 |
| Tramadol Hcl | Tramadol Hcl | 36 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 32 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 32 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 31 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 31 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 30 | 13 |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Armour Thyroid | Thyroid,pork | 27 | suppressed |
| Telmisartan | Telmisartan | 27 | suppressed |
| Verapamil Er | Verapamil Hcl | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 21 |
| Colchicine | Colchicine | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 19 |
| Valsartan | Valsartan | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | 12 |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 25 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 19 |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Gemtesa | Vibegron | 21 | suppressed |
| Chlordiazepoxide-Clidinium | Chlordiazepoxide/Clidinium Br | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Fentanyl | Fentanyl | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Constulose | Lactulose | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Np Thyroid | Thyroid,pork | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 15 |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 15 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Dipyridamole | Dipyridamole | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Keppra | Levetiracetam | 12 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Rytary | Carbidopa/Levodopa | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Topamax | Topiramate | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $360.88 · 20 records | Novo Nordisk Inc | ACCRUFER, Dexcom G6 Transmitter, Doc Band, ELIQUIS, EVENITY, FANAPT, FREESTYLE LIBRE, GEMTESA, JARDIANCE, NURTEC ODT, Ozempic, Rybelsus, Saxenda, The Cologuard Plus Collection Kit, VRAYLAR, Wegovy, XIFAXAN | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error